Histogenics Corporation, a late stage company focused on regenerative medicine technologies, today announced that John H. Johnson has been appointed to the company’s board of directors. Mr. Johnson is currently the chairman, president and chief executive officer of Dendreon Corporation.
“We are pleased to welcome John to our board of directors,” said Garheng Kong, M.D., Ph.D., chairman of the board of directors, Histogenics. “John’s extensive industry experience in both large pharma organizations as well as venture-backed companies will be a tremendous asset for the Histogenics team.”
Help employers find you! Check out all the jobs and post your resume.
